blood

Bringing Out the Big Guns Against Blood Cancer

IRP Research Shows Benefits of More Intensive Treatments for Certain Patients

woman receiving chemotherapy treatment

Fate can be cruel, especially when it comes to a rare, highly fatal blood cancer called acute myeloid leukemia (AML). Even when months of intensive chemotherapy appear to cause a complete remission of the disease — meaning doctors cannot detect any remaining cancer cells in a patient’s body — roughly half of those patients see the cancer return within two years, or even as soon as six months. Sadly, most of them don’t survive their second bout with the disease.

As a medical student, IRP senior investigator Christopher Hourigan, M.D., D.Phil., thought this outcome was unfair. More than that, he thought it indicated that the standard ways doctors determined if an AML patient was in remission were inadequate, and that remission might not even be the right goal. That’s why he has focused his career on finding ways to detect, prevent, and treat AML recurrence, known in his field as ‘relapse’.

“I was a scientist before I became a doctor, and it was really eye-opening to me, when I started to practice medicine, how difficult some of the treatment decisions were and how limited the information available was to inform those decisions,” Dr. Hourigan says.

Pain Research Center Accelerates IRP Pain Studies

Dedicated Staff and Cutting-Edge Technology Helps Solve Pain’s Many Mysteries

collage of researchers working with volunteers

For such a common ailment, pain remains a significant mystery. Part of the challenge of studying it is that it occurs in so many conditions and can vary from a mild ache to life-altering misery. Fortunately for both pain patients and IRP researchers studying pain, the NIH Pain Research Center has the technology and expertise to power new discoveries about pain in its many, complex forms.

On March 31 and April 1, NIH’s National Center for Complementary and Integrative Health (NCCIH) hosted a two-day virtual symposium titled “Tackling Pain at the National Institutes of Health: Updates From the Bench, the Clinic, and the New NIH Pain Research Center,” which featured presentations from a number of IRP scientists exploring important questions related to pain. Read on to learn more about some of the research discussed during that event, including efforts examining pain in patients with rare diseases, early-phase clinical trials of a new pain treatment, and investigations of how psychological factors can affect the way people experience pain.

Introducing NIH’s Newest Lasker Scholars

Program Gives Boost to Early Stage Investigators

Alison Boyce, Ian Myles, Jacqueline Mays, Yogen Kanthi, and Stephanie Chung

If TV shows like The Voice and America’s Got Talent are any indication, there are many extremely talented people out there who could become huge successes if presented with the right opportunity. This is no less the case in science, with thousands of extremely bright individuals quietly toiling away in their mentors’ labs as they await the chance to establish research programs of their own.

Fortunately, initiatives like the NIH’s Lasker Clinical Research Scholars Program exist to boost promising young researchers on to the next stage of their careers. Every year, the Lasker program allows a small group of early stage physician-scientists to establish their own labs at the NIH and carry out independent clinical research there for at least five years.

The five talented investigators selected as 2020 Lasker Scholars are pursuing a wide range of research questions, from how the immune system influences blood clotting to the mechanisms driving a rare and devastating skeletal disorder. Read on to learn more about the latest crop of researchers ramping up IRP labs of their very own.

Blood Test Predicts Premature Labor

First-Trimester Blood Analysis Could Enable Earlier, More Effective Intervention

mother and baby sleeping next to each other

Imagine a world in which pregnant women routinely travel to places of healing and meet with wise sages who examine a bit of their blood to divine when their babies will be born. While this may sound like something out of Greek mythology, it may soon become a reality, as IRP researchers have developed a test that was able to use blood samples taken early in pregnancy to identify women who would later deliver their babies prematurely.

Cellular Garbage Aids Quest for Alzheimer’s Blood Test

Experimental Approach Predicts Future Alzheimer’s Diagnoses

exosomes

If you looked through my garbage, you would probably find a litany of apple cores (my favorite fruit) and a couple fundraising requests from my alma mater. Similarly, scientists can learn a lot about what is going on in cells by examining their trash. IRP researchers recently developed a blood test that may be able to predict Alzheimer’s disease years before the onset of symptoms by examining packages of waste products from neurons.

A Look Back at the Legacy of Theodor Kolobow

The IRP has been home to a number of truly remarkable scientists who spent decades making discoveries and developing technologies that would go on to improve the lives of many. One of these giants was Theodor Kolobow, M.D., who passed away in March of last year at age 87. During his many years at the NIH's National Heart, Lung, and Blood Institute (NHLBI), Dr. Kolobow made momentous contributions to the study of our lungs and cardiovascular systems, including advancements in the development of artificial organs and key insights into the biological processes behind acute lung injury. 

Dr. Kolobow's legacy lives on not only through his colleagues' fond memories and his lasting influence on medical practice, but also through the NIH's historical archives. Read on for a tour through Dr. Kolobow's life and career, as can only be told by the Office of NIH History. 

Dr. Theodor Kolobow

Inflammation Cuts Lifeline for Blood-Producing Stem Cells

Discovery Could Lead to New Approaches for Boosting Blood Cell Counts

red blood cell (left), platelet (middle), and white blood cell (right)

Much of human biology is a black box — scientists know the key players and the end results, but not how those outcomes come about. Consequently, it remains a mystery why some medications help patients. A new IRP study has cracked open the black box to reveal how high levels of an inflammatory molecule inhibit blood cell production in some individuals and why a particular medicine helps reverse this life-threatening condition.

Ebola Virus: Lessons from a Unique Survivor

Reblogged from The NIH Director's Blog.

Ebola virus (green) is shown on cell surface

There are new reports of an outbreak of Ebola virus disease in the Democratic Republic of Congo. This news comes just two years after international control efforts eventually contained an Ebola outbreak in West Africa, though before control was achieved, more than 11,000 people died—the largest known Ebola outbreak in human history. Many questions remain about why some people die from Ebola and others survive. Now, some answers are beginning to emerge thanks to a new detailed analysis of the immune responses of a unique Ebola survivor, a 34-year-old American health-care worker who was critically ill and cared for at the NIH Special Clinical Studies Unit in 2015.

Exercise Releases Brain-Healthy Protein

Reblogged from the NIH Director's Blog.

Five images of different exercise activities

We all know that exercise is important for a strong and healthy body. Less appreciated is that exercise seems also to be important for a strong and healthy mind, boosting memory and learning, while possibly delaying age-related cognitive decline. How is this so? Researchers have assembled a growing body of evidence that suggests skeletal muscle cells secrete proteins and other factors into the blood during exercise that have a regenerative effect on the brain.